FDA 483 - Douglas Glenn Young, M.D. - November 20, 2023

An FDA inspection of Clinical Investigator Douglas Glenn Young in Sacramento, CA, revealed significant deviations from the investigational plan. The inspection found that staff were not properly trained prior to performing clinical trial activities, leading to incorrect dosing of investigational drugs for multiple subjects. These findings indicate a failure to ensure proper conduct and oversight of the clinical study.